Rafael Vázquez-Romo

Abstract PO3-20-02: Olaparib front line therapy with endocrine therapy in locally advanced unresectable or in metastatic breast cancer: OFELIA TRIAL

Carlos Arturo González Núñez, Paula Cabrera‐Galeana, Juan Enrique Bargalló Rocha, Rafael Vázquez-Romo et autres

Abstract INTRODUCTION: Currently, patients with recurrent or metastatic hormone-sensitive breast cancer are treated with endocrine therapy (ET) in combination with cyclin inhibitors, as it has been shown to improve both overall survival and progression-free survival. However, it has been observed that patients …

mx, co (code pays fourni par la source)

Abstract PO4-16-11: De-escalation of anthracyclines during adjuvant therapy based on Oncotype RS: A single institution experience in Mexico City

Carlos Arturo González Núñez, Paula Cabrera‐Galeana, Juan Enrique Bargalló Rocha, Rafael Vázquez-Romo et autres

Abstract Introduction: In Mexico, hormone positive HER2 negative breast cancer is the most frequent subtype, accounting for 76.6% of cases. For patients undergoing local control management through surgery; adjuvant chemotherapy is usually followed depending on different risk factors. In order to avoid …

mx, co (code pays fourni par la source)

Eficacia de las intervenciones psicológicas en la atención de problemas de imagen corporal en pacientes con cáncer de mama

Liliana Rivera-Fong, Rafael Vázquez-Romo, Enrique Bargalló‐Rocha, José Luis Aguilar-Ponce et autres

En los últimos años se han desarrollado diversas intervenciones psicológicas especializadas para disminuir el efecto negativo en la imagen corporal en pacientes con cáncer de mama; sin embargo, no se cuenta con revisiones sistemáticas que permitan valorar su eficacia. Objetivo. Evaluar la …

mx (code pays fourni par la source)

Pathogenic variant profile in DNA damage response genes correlates with metastatic breast cancer progression-free survival in a Mexican-mestizo population

Rafael Vázquez-Romo, Oliver Millán-Catalán, Erika Ruíz‐García, Antonio Daniel Martínez-Gutiérrez et autres

Introduction: Metastatic breast cancer causes the most breast cancer-related deaths around the world, especially in countries where breast cancer is detected late into its development. Genetic testing for cancer susceptibility started with the BRCA 1 and 2 genes. Still, recent research has …

mx (code pays fourni par la source)

ASO Visual Abstract: The Intensity of LKB-1 Expression, High-Risk Histopathology and TNM Stages are Independent Prognostic Factors in Oral Cavity Carcinoma

José F. Carrillo, Christian I. Cruz-Romero, Alejandro Avilés‐Salas, Liliana C. Carrillo et autres

mx (code pays fourni par la source)

LKB-1 Expression and High-Risk Histopathology are Independent Prognostic Factors for Patients with Oral Cavity Carcinoma

José F. Carrillo, Christian I. Cruz-Romero, Alejandro Avilés‐Salas, Liliana C. Carrillo et autres

mx (code pays fourni par la source)

Abstract PS1-05: Trends in breast-conserving surgery in Mexico after the implementation of a public health insurance system

Enrique Bargalló‐Rocha, Nancy Reynoso‐Noverón, J. Corona, Nereida Esparza‐Arias et autres

Abstract Introduction Although temporal trends in breast conserving surgery (BCS) have been described for developed countries like the United States (US), there is a lack of information regarding the uptake of breast conservation in developing regions of the world. In developing countries, …

mx (code pays fourni par la source)

Treatment of Unresectable Differentiated Thyroid Carcinoma With Upfront External Radiotherapy and Salvage Surgery: A STROBE-Compliant Retrospective Cohort Study

José F. Carrillo, Jesús Manuel Flores, Gilberto Espinoza-Macías, Rafael Vázquez-Romo et autres

INTRODUCTION: In patients with unresectable Differentiated thyroid cancer (DTC), the use of external beam radiation therapy (EBRT), leads mostly to palliation. Our aim is to define the role of upfront EBRT, followed or not by salvage surgery, on Progression-free survival (PFS) or …

mx (code pays fourni par la source)

Análisis del comportamiento clínico-patológico del cáncer de mama mucinoso: primer estudio multicéntrico en México. Revisión a 10 años

María Elena Lara Hernández, Gerardo Cuamani-Mitznahuatl, Cindy Aideé Nájera Muñoz, Daniel Maciel Hernández et autres

mx (code pays fourni par la source)

216P The impact of pregnancy-associated breast cancer (PABC) according to immunohistochemical (IHC) subtype: A matched case-control study

W. Muñoz-Montaño, Cynthia De la Garza‐Ramos, Ariana Tabares, Paula Cabrera‐Galeana et autres

mx (code pays fourni par la source)

Effectiveness of ultrasound in the detection of axillary metastasis in patients with breast cancer without clinical evidence of axillary disease: Clinical impact

Gerardo Cuamani-Mitznahuatl, Héctor Isaac Rocha-­González, Christian H. Flores-Balcázar, Guadalupe Elizabeth Trejo-Durán et autres

mx (code pays fourni par la source)

Abstract P2-14-16: Optimal timing to initiate adjuvant chemotherapy in Mexican women with high risk luminal breast cancer

Paula Cabrera‐Galeana, Leticia Mendoza-Oliva, Cynthia Villarreal‐Garza, Rafael Vázquez-Romo et autres

Abstract Background: It is well known that the interval time (IT) to begin adjuvant chemotherapy (ADYCT) after surgical treatment, it is important to achieve better outcomes in breast cancer (BC), patients. After an IT of more than 91 days, the benefit of …

mx (code pays fourni par la source)